Rafferty Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Rafferty Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.7M	Sell	159,581 -40,177	-20%	-$562K	0.01%	570
2026 Q1	$2.56M	Sell	199,758 -15,670	-7%	-$200K	0.01%	557
2025 Q4	$1.94M	Buy	215,428 +32,337	+18%	+$445K	0.01%	652
2025 Q3	$3.16M	Buy	183,091 +54,298	+42%	+$669K	0.01%	537
2025 Q2	$1.21M	Sell	128,793 -51,299	-28%	-$421K	﹤0.01%	726
2025 Q1	$1.28M	Sell	180,092 -75,112	-29%	-$759K	0.01%	686
2024 Q4	$2.98M	Sell	255,204 -344	-0.1%	-$5.37K	0.01%	528
2024 Q3	$5.25M	Buy	255,548 +30,336	+13%	+$699K	0.02%	412
2024 Q2	$5.04M	Sell	225,212 -98,349	-30%	-$2.34M	0.02%	413
2024 Q1	$8.9M	Sell	323,561 -5,437	-2%	-$151K	0.03%	307
2023 Q4	$10M	Buy	328,998 +77,873	+31%	+$2.24M	0.04%	278
2023 Q3	$7.94M	Buy	251,125 +42,757	+21%	+$1.66M	0.05%	287
2023 Q2	$8.5M	Sell	208,368 -3,020	-1%	-$122K	0.05%	246
2023 Q1	$7.88M	Sell	211,388 -23,076	-10%	-$905K	0.05%	249
2022 Q4	$8.18M	Buy	234,464 +104,805	+81%	+$4.98M	0.07%	253
2022 Q3	$7.26M	Buy	129,659 +13,740	+12%	+$852K	0.08%	207
2022 Q2	$6M	Buy	115,919 +26,198	+29%	+$1.33M	0.06%	253
2022 Q1	$6.52M	Buy	89,721 +41,867	+87%	+$3.55M	0.04%	301
2021 Q4	$5.66M	Buy	47,854 +28,463	+147%	+$3.57M	0.03%	338
2021 Q3	$2.6M	Sell	19,391 -11,191	-37%	-$1.69M	0.02%	552
2021 Q2	$4.95M	Sell	30,582 -20,273	-40%	-$1.58M	0.03%	322
2021 Q1	$4.08M	Buy	50,855 +33,351	+191%	+$2.24M	0.03%	334
2020 Q4	$952K	Sell	17,504 -64,161	-79%	-$2.33M	0.01%	513
2020 Q3	$1.62M	Buy	81,665 +57,319	+235%	+$1.2M	0.02%	474
2020 Q2	$512K	Buy	+24,346	New	+$414K	0.01%	707
2020 Q1	–	Sell	-45,492	Closed	-$667K	–	742
2019 Q4	$667K	Sell	45,492 -58,958	-56%	-$820K	0.01%	639
2019 Q3	$1.39M	Buy	104,450 +11,860	+13%	+$189K	0.02%	469
2019 Q2	$1.52M	Buy	92,590 +12,871	+16%	+$202K	0.03%	483
2019 Q1	$1.36M	Buy	+79,719	New	+$1.19M	0.02%	493

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Rafferty Asset Management's NTLA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, selling an estimated $562K and leaving 159,581 shares worth $2.7M. The position accounts for 0.01% of the portfolio, ranked #570.

Rafferty Asset Management first reported a position in NTLA in Q1 2019 and has held it in 29 quarters since. The position peaked at $10M in Q4 2023. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Rafferty Asset Management held 159,581 shares of Intellia Therapeutics worth $2.7M as of Q2 2026.
Rafferty Asset Management sold 40,177 Intellia Therapeutics shares in Q2 2026, an estimated $562K.
Intellia Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #570 holding.
Rafferty Asset Management first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 29 quarters since.
Rafferty Asset Management's Intellia Therapeutics position peaked at $10M in Q4 2023.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.